Inventiva (NASDAQ:IVA) Stock Falls 5.5% After Earnings Miss

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) fell 5.5% during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $3.33 and last traded at $3.3350. 2,176,702 shares were traded during mid-day trading, an increase of 180% from the average session volume of 778,476 shares. The stock had previously closed at $3.53.

The company reported ($0.14) earnings per share for the quarter. The company had revenue of $0.75 million for the quarter.

Key Stories Impacting Inventiva

Here are the key news stories impacting Inventiva this week:

• Positive Sentiment: Inventiva reported cash and cash equivalents of approximately €166.1 million at the end of the first half, strengthening its balance sheet ahead of the Phase 3 NATiV3 results. Management maintained its cash runway through the end of the second quarter of 2027, reducing near-term financing concerns. Inventiva strengthens cash position before NATiV3 results Inventiva cash runway remains unchanged
• Positive Sentiment: First-half net loss narrowed substantially from the prior-year period, improving the company’s cost and cash-burn profile. Investors are also focused on the expected NATiV3 Phase 3 readout for lanifibranor in MASH, which is anticipated this quarter and represents the company’s most important near-term catalyst. Inventiva first-half loss plunges and MASH readout approaches
• Positive Sentiment: Several market opinions remain favorable, helping reinforce optimism around Inventiva’s clinical pipeline and the potential value of a successful NATiV3 outcome. Inventiva receives several positive opinions
• Neutral Sentiment: The company’s first-half update and earnings presentation emphasize that the investment case remains centered on clinical execution rather than current product revenue. Inventiva first-half financial results and corporate update
• Negative Sentiment: The latest quarterly release reported a loss of $0.28 per share versus the $0.20 expected loss, while revenue of $0.02 million was far below the $2.88 million consensus estimate. The earnings shortfall may limit gains until investors receive clearer evidence from the NATiV3 trial. Inventiva quarterly earnings report

Wall Street Analysts Forecast Growth

IVA has been the topic of a number of recent analyst reports. Guggenheim lifted their price objective on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Cantor Fitzgerald assumed coverage on Inventiva in a research note on Friday, July 17th. They set an “overweight” rating for the company. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Inventiva presently has an average rating of “Buy” and a consensus target price of $15.75.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Engineers Gate Manager LP grew its stake in Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares during the period. Persistent Asset Partners Ltd acquired a new position in Inventiva in the fourth quarter valued at approximately $603,000. Seven Fleet Capital Management LP bought a new position in shares of Inventiva during the 1st quarter worth approximately $1,111,000. Eventide Asset Management LLC acquired a new stake in shares of Inventiva during the 4th quarter worth approximately $1,155,000. Finally, Propel Bio Management LLC bought a new stake in shares of Inventiva in the 4th quarter valued at $4,650,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Stock Performance

The stock’s 50-day moving average is $4.41 and its 200-day moving average is $4.73.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.